It is a paper public limited company based in Mumbai, Maharashtra, India, established in 2024.
2024 | Mumbai, Maharashtra, India | ActiveAlixer Nexgen Therapeutics Limited, a active public limited company, was established on 12 July 2024 in Mumbai, Maharashtra, India. Engaging in paper & paper products within the paper sector, it holds CIN: U21001MH2024PLC428703. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹100.00 Cr and a paid-up capital of ₹25.20 Cr.
Its leadership includes Madhurima Singh (Whole-Time Director), Vikas Gupta (Director), Akhilesh Dayanand Sharma (Director). Past directors included Aniruddha Singh, Basudeo Narayan Singh, Manish Narang. Its latest AGM occurred on 22 August 2025, with the balance sheet filed on 31 March 2025. It is based at Alkem House, Senapati, Bapat Marg, Lower Parel, Mumbai, Maharashtra, 400013.
U21001MH2024PLC428703
428703
12 July 2024
₹100.00 Cr
₹25.20 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Alixer Nexgen Therapeutics Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Madhurima Singh | Whole-Time Director | 12 Jul 2024 | Current |
| Vikas Gupta | Director | 12 Jul 2024 | Current |
| Akhilesh Dayanand Sharma | Director | 12 Jul 2024 | Current |
| Srinivas Balmiki Prasad Singh | Whole-Time Director | 12 Jul 2024 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Individual Subscriber | - | Past |
| Pramod Abcsdd | Non- Individual Subscriber | - | Past |
| Pramod Abcsdd | Individual Subscriber | - | Past |
| Pramod Abcsdd | Individual Subscriber | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Enhance accessibility to Alixer Nexgen Therapeutics's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
Unlock access to Alixer Nexgen Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Alixer Nexgen Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Alixer Nexgen Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alixer Nexgen Therapeutics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Alixer Nexgen Therapeutics Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records. was documented.
Alixer Nexgen Therapeutics Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was recorded as a recent event.
Madhurima Singh was appointed as a Whole-time director was appointed as a Whole-time director on 12 Jul 2024 & has been associated with this company since 1 year 6 months . was recorded as a recent event.
Progress on Vikas Gupta was appointed as a Director was appointed as a Director on 12 Jul 2024 & has been associated with this company since 1 year 6 months . was documented.
The activity Akhilesh Dayanand Sharma was appointed as a Director was appointed as a Director on 12 Jul 2024 & has been associated with this company since 1 year 6 months . was completed.
Srinivas Balmiki Prasad Singh was appointed as a Whole-time director was appointed as a Whole-time director on 12 Jul 2024 & has been associated with this company since 1 year 6 months . was recorded as a recent event.
The CIN of Alixer Nexgen Therapeutics Limited is U21001MH2024PLC428703.
Alixer Nexgen Therapeutics Limited is headquartered at Alkem House, Senapati, Bapat Marg, Lower Parel, Mumbai, Maharashtra, 400013.
Alixer Nexgen Therapeutics Limited was incorporated on 12 July 2024.
The current directors of Alixer Nexgen Therapeutics Limited are
The primary industry of Alixer Nexgen Therapeutics Limited is Paper.
Alixer Nexgen Therapeutics Limited is unlisted.
The authorized capital of Alixer Nexgen Therapeutics Limited is ₹100.00 Cr, and the paid-up capital is ₹25.20 Cr.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX